FDA sends warning letter to Novo Nordisk over failure to report deaths, adverse side effects of GLP-1s

Source: The Hill News · Bias: Center

Summary

The U.S. Food and Drug Administration (FDA) has issued a warning to Novo Nordisk over its alleged failure to report adverse side effects, including death, in patients who took its GLP-1 medications, popularly known as Ozempic and Wegovy. The FDA wrote in a March 5 letter that it observed “serious violations” of reporting requirements during…

Related Coverage

More Headlines From March 10, 2026

FDA sends warning letter to Novo Nordisk over failure to report deaths, adverse side effects of GLP-1s
The Hill News

FDA sends warning letter to Novo Nordisk over failure to report deaths, adverse side effects of GLP-1s

Center

The U.S. Food and Drug Administration (FDA) has issued a warning to Novo Nordisk over its alleged failure to report adverse side effects, including death, in patients who took its GLP-1 medications, popularly known as Ozempic and Wegovy. The FDA wrote in a March 5 letter that it observed “serious violations” of reporting requirements during…